- AstraZeneca said that its drug to treat patients with non-small cell lung cancer had received marketing authorisation from China's National Medical Products Administration.

The approval of the lung cancer eImfinzi was based on results from the primary analysis of progression-free survival (PFS) and supported by overall survival (OS) from the Phase III pacific trial, both published in The New England Journal of Medicine.

Imfinzi reduced the risk of death by 32% and prolonged the time patients lived without disease progression or death by more than 11 months.

'This approval illustrates our long-standing commitment to improving health outcomes in China, where more than one-third of the world's lung cancer diagnoses and deaths occur. As the global standard of care in this curative-intent setting, Imfinzi is an important new option for patients in China,' said Dave Fredrickson, executive vice president, oncology business unit,

Story provided by